5 Key Takeaways

• 1

  The FDA approved marstacimab-hncq (HYMPAVZI) for routine prophylaxis in hemophilia A and B patients aged 6 years and older.

• 2

  HYMPAVZI is the first subcutaneous non-factor therapy for pediatric patients aged 6 to 11 years with hemophilia B.

• 3

  In the phase 3 BASIS trial, marstacimab reduced the mean annualized bleeding rate by 93% compared to on-demand intravenous treatment.

• 4

  Marstacimab targets the Kunitz 2 domain of tissue factor pathway inhibitor to restore balance between bleeding and coagulation.

• 5

  Common adverse reactions include injection-site reactions, headache, and pyrexia, with warnings for thromboembolic events and hypersensitivity.